Platinum-resistant Ovarian Cancer Recruiting Phase 1 / 2 Trials for Surufatinib (DB15106)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

IndicationStatusPhase
DBCOND0068919 (Platinum-resistant Ovarian Cancer)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05494580Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian CancerTreatment